AstraZeneca settles for $520 million following investigation into improper marketing of anti-psychotic drug

Share this article:

Pharmaceutical giant AstraZeneca has agreed to pay $520 million to end a federal investigation into its alleged illegal marketing of the drug Seroquel for off-label uses, according to reports from Washington.

The Justice Department has accused AstraZeneca of misleading physicians by emphasizing research favorable to Seroquel, and downplaying potentially dangerous side effects, such as diabetes and increased risk of death for elderly patients with dementia, according to The New York Times. Though it is not illegal to use drugs for off-label purposes, it is illegal to market them for those uses. A 2009 study found that as many as 20% of physicians who prescribed Seroquel for dementia treatment were unaware that the drug hadn't been approved for that use. (McKnight's, 8/26/09)

In October of last year, AstraZeneca set aside $520 million in an agreement with the United States attorney in Philadelphia, according to the Times. AstraZeneca made $4.9 billion in sales of Seroquel in 2009. The company has denied all allegations of wrongdoing. Off-label refers to the practice of prescribing a drug for a purpose other than what it was approved for by the Food and Drug Administration.

Share this article:

More in News

Skilled nursing facilities with poor quality ratings do not readmit more patients to hospitals, researchers find

Skilled nursing facilities with poor quality ratings do ...

Low-quality and high-quality skilled nursing facilities readmit about the same proportion of residents to hospitals, suggest research findings recently published in the American Journal of Medical Quality.

Cipro and related antibiotics increase MRSA risk in long-term care facilities, study ...

Long-term care residents on a fluoroquinolone antibiotic such as Cipro are at an increased risk for methicillin-resistant Staphylococcus aureus, researchers in France have found.

Jonathan Blum, who oversaw long-term care reforms, resigns as head of Medicare

The nation's top Medicare official, Jonathan Blum, is leaving his post next month, news outlets reported Tuesday. Blum became a familiar figure to long-term care providers through Open Door Forum calls and other outreach efforts during his five-year tenure, as he guided implementation of Medicare ...